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Bronchopulmonary dysplasia (BPD) is a major complication of preterm birth and has serious adverse long-term health
consequences. The etiology of BPD is complex, multifactorial, and incompletely understood. Contributing factors include
ventilator-induced lung injury, exposure to toxic oxygen levels, and infection. Several preventive and therapeutic strategies have
been developed with variable success. These include lung protective ventilator strategies and pharmacological and nutritional
interventions. These strategies target diﬀerent components and stages of the disease process and they are commonly used in
combination. The purpose of this review is to discuss the evidence for current pharmacological interventions and identify future
therapeutic modalities that appear promising in the prevention and management of BPD. Continued improved understanding of
BPD pathogenesis leads to opportunities for newer preventive approaches. These will need to be evaluated in the setting of current
clinical practice in order to assess their eﬃcacy.
1.Introduction
Bronchopulmonary dysplasia (BPD) remains a major com-
plication of prematurity resulting in signiﬁcant mortality
and morbidity despite advances in perinatal care and decline
in mortality rates among very low birth weight (VLBW)
infants [1]. Increased survival among VLBW infants con-
tributes to the overall increase in the incidence of BPD
and currently infants with birth weights <1250 grams ac-
count for 97% of cases of BPD [2]. The long-term health
consequences of BPD include respiratory disease that can
persist into adulthood and increased susceptibility to respi-
ratoryinfections,asthma,pulmonaryhypertension,repeated
hospitalizations, neurodevelopmental impairment, and also
increasedmortality[3].TheetiologyofBPDismultifactorial
and includes exposure to mechanical ventilation, oxygen
toxicity, infection, and inﬂammation that contribute to
arrested alveolar development and associated abnormal vas-
cular growth and damage to the distal airways of the highly
vulnerable premature lung [4]. Multiple pharmacological
andnonpharmacologicalapproacheshavebeenproposed for
the prevention or treatment of preterm lung injury and BPD.
While antenatal steroids, protective ventilation strategies,
targeted oxygen saturation goals, caﬀeine therapy, vitamin
A therapy, and optimization of nutrition have helped to
modestlyimproveBPDoutcomes,mostcurrenttherapiesare
supportive[4,5].Manytherapiesremaincontroversialdueto
unacceptable side eﬀects and others continue to need further
studyincludingrandomizedcontrolledtrialtestingandlong-
term outcome follow-up analysis.
Inthisreview,wepresentthecurrentandpotentialfuture
pharmacologic approaches for the prevention and man-
agementofBPDbasedonpublishedmeta-analyses,random-
ized controlled trials, systematic reviews, individual clinical
studies, and emerging work from animal models of disease.
Acomprehensivelistofthedrugsdiscussedintheprevention
and management of BPD is shown in Table 1.
2. Caffeine
Caﬀeine is a methylxanthine commonly used in the treat-
ment of apnea of prematurity, a common complication of2 International Journal of Pediatrics
Table 1: Pharmacological interventions for prevention and management of BPD.
Class of drugs Presumed mechanism Main clinical responses Major side eﬀects Recommended use in BPD
Caﬀeine Apnea of prematurity
Unknown
R e d u c t i o ni nd a y so f
positive pressure
ventilation, reduction in
BPD, lower incidence of
neurodevelopmental
impairment
Transient decrease in
weight gain
Recommended for
treatment of apnea of
prematurity and
prevention of BPD
Diuretics (loop,
thiazides) Pulmonary Edema Decreased pulmonary
edema
Electrolyte imbalance,
osteopenia, ototoxicity
Loop: use sparingly in early
evolving BPD Thiazides:
Consider for judicious
chronic use
Bronchodilators
(albuterol,
ipratropium)
Bronchospasm Bronchodilation Tachycardia, arrhythmias
Limit use in infants with
bronchospasm and acute
clinical response
Steroids (early,
moderately early, late,
inhaled)
Inﬂammation Improved oxygenation,
earlier extubation
Short term: hyperglycemia,
hypertension, GI
perforation
Long term: increased risk
for cerebral palsy
Last resort therapy for
rapidly deteriorating
pulmonary status
Mast cell stabilizer
(cromolyn) Inﬂammation No clinical beneﬁt None reported Not for routine use
Vitamin A Impaired lung
development
Small reduction in
incidence of BPD None reported Recommended in infants
<1000 grams
Inositol Impaired lung growth Decreased incidence of
BPD None reported Not for routine use
Antioxidants (SOD,
NAC,Vitamin E,
vitamin C)
Oxidant injury Delayed beneﬁt from SOD None reported Not for routine use
Inhaled NO
Inﬂammation
Oxidant stress
Unknown
Possibly beneﬁcial in
reducing BPD but optimal
timing, dose and duration
unknown
IVH in infants <1000g
with early rescue use
Not for routine or rescue
use
Modiﬁed from Baveja and Christou [10].
prematurity occurring in at least 85 percent of infants who
are born at less than 34-week gestation [6, 7]. Methylxan-
thines have been shown to reduce the frequency of apnea of
prematurity and need for mechanical ventilation during the
ﬁrst seven days of therapy [8] .Ar e c e n tl a r g er a n d o m i z e d
controlled trial followed primary outcome of long-term
neurodevelopment and secondary short-term outcomes of
rates of BPD in infants with birthweights from 500 to 1250
grams [8]. Infants in the caﬀeine group were found to have
an incidence of BPD of 36% compared to 47% of infants
in the placebo group [8]. Patients in the caﬀeine group had
r e d u c e dw e i g h tg a i n ,b u tt h i sw a sf o u n dt ob et e m p o r a r y .
Long-term follow-up at 18 to 22 months showed that infants
assigned to the caﬀeine group had a lower incidence of
neurodevelopmental impairment including lower rates of
cerebral palsy and lower rates of cognitive delay [9]. The
potential mechanism of the eﬀect of caﬀeine on decreased
incidence of BPD remains unknown. The number of days
on positive pressure ventilation was decreased by one week
in the infants assigned to the caﬀeine group which could
account for potential reduction in ventilator-induced lung
injury in the caﬀeine group [8, 9]. When interpreting this
secondary outcome of caﬀeine leading to a decreased rate
of BPD, it is important to take into consideration that
the randomization protocol eﬀectively excluded infants who
needed mechanical ventilation for greater than 10 days, in
other words infants at a presumably higher risk for BPD.
In conclusion, the evidence supports the use of caﬀeine in
treatmentofapneaofprematuritywithﬁndingsofsecondary
beneﬁts including reduction in BPD rates and improved
neurodevelopmental outcomes.
3.Diuretics
Diuretics are a common class of drugs used in the man-
agement of BPD. Interstitial alveolar edema appears to be
a prominent feature of BPD and excessive interstitial edema
can lead to decreased lung compliance. Iatrogenic increase in
ﬂuid administration, capillary leak from inﬂammation due
to infection or from ventilator-induced lung injury, and vol-
ume overload due to left to right shunting through a patent
ductus arteriosus are some of the factors that contribute to
pulmonary edema [11–13]. Diuretics potentially beneﬁt by
increasing reabsorption of ﬂuid from the lung.International Journal of Pediatrics 3
(a) Loop Diuretics. Loop diuretics act by blocking the
luminal Na-K-2Cl transporter in the thick ascending limb
of the loop of Henle. Loop diuretics compete for the chlo-
ride site on this transporter and diminish reabsorption.
Furosemide is the most widely administered loop diuretic
in neonates; yet its use remains controversial. A Cochrane
meta-analysis has reviewed several small trials that studied
the risks and beneﬁts of systemic furosemide on preterm
infants with BPD [14]. Minimal eﬀect was observed with
enteral furosemide in preterm infants <3w e e k so fa g e[ 14].
Chronic administration of furosemide for a week improved
short-term outcomes of pulmonary compliance, oxygen
requirement, and minute ventilation in preterm infants
>3 weeks of age with BPD [15–17]. However, no existing
trials have addressed long-term outcomes including eﬀect
on duration of oxygen requirement, weaning oﬀ mechanical
ventilation, duration of hospital stay, incidence of BPD, and
mortality [14].
Administration of aerosolized furosemide has also been
explored in an eﬀort to minimize systemic side eﬀects in
preterm infants with evolving BPD. A Cochrane meta-anal-
ysis reviewed 8 trials with aerosolized furosemide and noted
that a single-aerosolized dose of furosemide may transiently
improve pulmonary mechanics in preterm infants >3w e e k s
of age [18]. There was no signiﬁcant pulmonary improve-
mentwithchronicadministrationofaerosolizedfurosemide.
None of these studies examined delivery of the drug to the
distal airways or serum levels. Furthermore, the studies had
inadequate assessment of clinical outcomes such as duration
of mechanical ventilation, oxygen requirement, length of
stay, incidence of BPD, mortality, and complications of
treatment.
In summary, the data on the use of furosemide is limited.
Potential risks of loop diuretic therapy such as electrolyte
imbalance, ototoxicity, nephrocalcinosis, and osteopenia
along with inconclusive data on long-term primary and sec-
ondary outcomes warrant future trials to justify the chronic
use of furosemide in current clinical practice. Current evi-
dence does not support use of loop diuretics for prevention
of BPD and use of furosemide sparingly to acutely treat
pulmonary edema is currently the preferred practice.
(b) Thiazides. Thiazides eﬀect the early portion of the distal
tubule and bind directly to the chloride site of the elec-
troneutral sodium chloride channel. The risk of electrolyte
abnormalities is far less with thiazide diuretics compared to
loopdiureticsduetothesmallamountofsodiumabsorption
occurring in the distal tubule. A Cochrane meta-analysis
examined six studies on the use of thiazides in preterm
infants and found that chronic use of thiazides improves
lung mechanics and decreases the need for supplemental
furosemide boluses [19]. In a randomized double-blind
placebo-controlled trial thiazide and spironolactone were
given to 43 nonintubated BPD patients until they no longer
required oxygen supplementation [20]. The study showed
decreased oxygen requirement and improved lung function
in the treatment group compared to placebo but failed to
show any improvement in the survival rate, duration of
oxygen requirement, or length of hospital stay. In intubated
patients, a lower oxygen requirement and better lung com-
pliance and decreased administration of furosemide boluses
in the treatment group compared to placebo were found
in one study, but with no change in airway resistance [21].
Administration of thiazides did not decrease the length of
hospital stay, need for ventilator support, or other long-
term outcomes. Addition of potassium-sparing diuretics
such as spironolactone which act exclusively on the Na−K/H
exchange mechanisms in the late distal tubule and cortical
collecting duct did not alter the compliance or oxygen
requirement compared to thiazides alone and had no eﬀect
on need for electrolyte supplementations [22].
Further studies on the role of chronic diuretics in the
treatment of BPD may be warranted in the current practice
era of antenatal steroids and surfactant therapy in order to
provide deﬁnitive evidence of their clinical usefulness. No
clear evidence is present for use of thiazide diuretics for the
prevention or management of BPD. Meanwhile thiazides are
the diuretics of choice in ventilator-dependent infants for
speciﬁc case-based administration and care should be taken
to avoid electrolyte abnormalities with appropriate sup-
plementation.
4. Bronchodilators
BPD causes increased airway resistance due to smooth
musclehypertrophyandhyperreactivity[3].Bronchodilators
are a common medication used to relieve bronchospasm
in asthmatic patients and have been studied in BPD pa-
tients. Studies have shown that bronchospasm contributes
to elevated pulmonary resistance in preterm infants and
bronchodilators improve dynamic compliance by lowering
pulmonary resistance [23–26]. Bronchodilators have been
broadly categorized into adrenergic and anticholinergic
agents. Their eﬀect is transient and both have been shown
to acutely reduce pulmonary resistance and increase compli-
anceinBPDpatients.Variabilityinindividualresponsiveness
to β-agonists may be genetically determined [27–29]. In
the Cochrane database only one trial addressed the use of
bronchodilators for the prevention of BPD and measured
long-termoutcomes[30].Thestudyenrolled173infants<31
weeks of gestational age, who needed ventilatory support
at the 10th postnatal day. They were randomized to four
groups and received either placebo, placebo with salbutamol
or beclomethasone, or both beclomethasone and salbutamol
for 28 days. No signiﬁcant eﬀects of the treatment on
incidence or severity of BPD, duration of ventilator support,
or oxygen therapy were observed.
The two most widely used bronchodilators are albuterol
andipratropium[23,31].Potentialsideeﬀectsofβ sympath-
omimetic agents include tachycardia, hypokalemia, arrhyth-
mias, and hyperglycemia. Inhaled anticholinergic agents,
in addition, decrease gastrointestinal motility and dry and
thicken respiratory secretions. Ipratropium has traditionally
been used along with albuterol to provide synergism. No
trials have yet investigated if a combination therapy of a beta
agonist and anticholinergic result in improved outcomes in
BPD compared to albuterol alone. Future trials are required4 International Journal of Pediatrics
to study various modes of delivery of the diﬀerent adrenergic
and anticholinergic drugs alone or in combination.
Due to a low number of trials and potential side eﬀects,
current evidence supports that bronchodilator therapy
should be limited to infants with evidence of bronchospasm
and continued only if there is a clinical response to therapy.
Even in these cases, there is no evidence that the long-term
outcome is altered.
5. Steroids
Inﬂammation is a main contributor to the pathogenesis
of BPD. Since corticosteroids are potent anti-inﬂammatory
agents, many trials have examined the use of steroids in BPD.
Systemic steroid administration reduces the inﬂammatory
response,producesarapidimprovementinpulmonaryfunc-
tion with better gas exchange, and facilitates weaning from
mechanical ventilation. In addition to the anti-inﬂammatory
eﬀects, steroids also enhance surfactant production, decrease
airway edema, stabilize capillary leakage, augment β adren-
ergic activity, and decrease overall lung ﬁbrosis [32–34].
Both systemic and inhaled corticosteroids have been studied
extensivelyinpretermneonatesforpreventionandtreatment
of BPD. The steroid trials may be categorized according to
the time of administration. Early administration is deﬁned
as less than eight days after birth. A Cochrane meta-analysis
reviewed that twenty-eight randomized controlled trials
evaluated eﬀects of early treatment of dexamethasone on the
incidence of BPD [35, 36]. Steroids facilitated extubation
and decreased the incidence of BPD. However, adverse
eﬀects such as hyperglycemia, gastrointestinal perforation,
hypertension, infection, steroid-induced cardiomyopathy,
and long-term neurodevelopmental eﬀects including cere-
bral palsy complicated the treatment. Moderately early
administration of dexamethasone (between 7 to 14 days) led
to similar decrease in the incidence of BPD and facilitated
extubation [37]. Nine trials studied late administration of
dexamethasone usually after 3 weeks [38]. These studies
showed transient improvement including increased success
rates of extubation and reduction of the need for later steroid
and home oxygen therapy compared to the controls. Both
moderately early and late treatments were complicated by
short- and long-term side eﬀects. The most worrisome long-
term eﬀect increased risk for poor neurological outcome
including cerebral palsy. As a result, the European Asso-
ciation of Perinatal Medicine, the American Academy of
Pediatrics, and the Canadian Pediatric Society have advised
against routine use of systemic dexamethasone for the
preventionortreatmentofBPD.Onestudyhasexaminedthe
use of low-dose dexamethasone (0.89mg/kg over 10 days)
in preterm infants who were ventilator dependent after 1
week of age [39]. The study showed decreased ventilator
requirement, improved oxygenation, and greater percentage
of successful extubation in the treatment group compared
to placebo. Although the study showed no short-term side
eﬀects such as hypertension or intestinal perforation, it
enrolled relatively “older” premature infants (mean gesta-
tional age 28-29 weeks) and no long-term outcomes were
included.
In summary, the evidence of long-term neurodevelop-
mental harm with administration of steroids is clear with
early (<8 day) administration of dexamethasone [36]. With
later administration (>7 days), the data trended towards
increasedcerebralpalsyalongwithatrendtowardsdecreased
mortality [37, 38].
Given these ﬁndings of increased likelihood of poor neu-
rological outcome, current evidence is clearly against the
early use of dexamethasone in the ﬁrst week of life. Later
use of dexamethasone should be undertaken with caution
and reserved for patients with BPD in whom weaning from
high ventilator settings and oxygen support is unsuccessful
or their respiratory status is rapidly deteriorating.
Recent arguments have questioned the use of dexam-
ethasone in the steroid trials and the possible role of other
steroids. Betamethasone, a stereoisomer of dexamethasone,
may have a diﬀerential role in preterm infants. Some have
reported concern of possible direct neuronal injury and
neurological side eﬀects from the preservatives such as
sulﬁtes present in dexamathasone and potential further
study of postnatal betamethasone may be warranted [40,
41]. Hydrocortisone prophylaxis for early adrenal insuﬃ-
ciency to prevent BPD was examined [42]. In this study,
preterm infants weighing less than 1kg and mechanically
ventilated were randomized to receive placebo or hydro-
cortisone, 1mg/kg/day for 12 days and then 0.5mg/kg/day
for 3 days. The study showed no signiﬁcant diﬀerences
in the survival rates between the two groups. However,
among infants exposed to chorioamnionitis, the ones treated
with hydrocortisone had signiﬁcantly lower mortality and
improved survival without BPD. There was no suppression
of adrenal function or short-term growth but a higher rate of
gastrointestinal perforation was seen in the hydrocortisone-
treated group receiving indomethacin compared to the
placebo group. Additional trials may be warranted in order
to determine the role of low-dose hydrocortisone therapy in
the prevention of BPD especially in preterm infants born to
mothers with chorioamnionitis.
Inhaled steroids have also been evaluated in an eﬀort
to optimize the beneﬁts of corticosteroids and minimize
unacceptable systemic side eﬀects. Inhaled steroids have
been tried early (<2 weeks of age) to prevent BPD and
later to treat established BPD [43, 44]. None of the trials
demonstrated signiﬁcant change on the BPD rate at 28 days
or 36 weeks postmenstrual age. Multiple trials examined the
eﬀectiveness of inhaled steroids administered to ventilator
dependent preterm infants after two weeks of life [45–
48]. These approaches oﬀered no advantage of aerosolized
corticosteroids over systemic therapy. Aerosolized steroids
did not have any signiﬁcant eﬀect on the mortality or
incidence of BPD, duration of ventilatory support, or
oxygen therapy. Major concerns with inhaled corticosteroids
included the type of steroids, their dosages, and uncer-
tainty regarding drug delivery. Studies have suggested that
delivery of aerosolized particles is limited by the size of
the particles, presence or absence of endotracheal tube to
facilitate delivery, diﬀerences in delivery device (i.e., MDI
versus spacer), and use of nebulizers. There is some evidence
that inhaled steroids are absorbed systemically and thusInternational Journal of Pediatrics 5
carry risks similar to systemic steroids. At the time of this
review, a multicenter randomized controlled clinical trial is
underway in Europe (NEuroSIS) aiming to examine whether
early administration of inhaled steroids in preterm infants
reduces the risk of BPD and includes short-term and long-
term outcomes which may answer questions regarding both
eﬃcacyaswellassafety.Duetotheirmultiplemechanismsof
action, steroids continue to oﬀer promise in the prevention
and management of BPD; however, the appropriate dose,
timing, and size of the glucocorticoid molecule need to be
further studied in order to maximize beneﬁt and minimize
risks. These studies must include long-term pulmonary
and neurodevelopmental follow-up in order to determine
whether the intervention is safe and eﬀective.
6.Mast CellStabilizer
Cromolyn, a mast cell stabilizer, is the ﬁrst nonsteroidal anti-
inﬂammatorydrugusedinasthmaticpatients.Ittargetsboth
sensitized and nonsensitized mast cells and prevents degran-
ulation and release of histamine. Mast cell stabilizers have
been shown to decrease neutrophil migration and activation
thus minimizing inﬂammation [49]. Two trials studied the
possible role of cromolyn in prevention and treatment of
evolving BPD [49, 50]. Though the sample sizes were small,
both studies showed no improvement in mortality, days on
mechanical ventilation, or incidence of BPD. Cytokine levels
were lower in the lung lavage ﬂuid in the treatment group
compared to the placebo [49]. These studies, similar to other
aerosolized drug studies, did not assess drug delivery, thus
failing to provide evidence for eﬀective drug deposition.
Current evidence does not support the use of cromolyn for
the prevention or treatment of BPD but further studies may
be warranted.
7.VitaminA
Vitamin A is a retinoid essential for the normal lung
growth and important in regulation of lung epithelial cell
repair. It is known that preterm infants have low levels
of Vitamin A at birth with low levels associated with an
increasedriskofchroniclungdisease[51].ACochranemeta-
analysis reviewed eight studies on the eﬃcacy of Vitamin
A supplementation in prevention of BPD. In extremely
low birth weight infants, supplementation was found to
decrease rates of BPD [52]. In the largest trial in the meta-
analysis, infants less than 1000 grams who received vitamin
A supplementation had an 8% decrease in rate of death
or BPD compared to the placebo group [53]. While this
meta-analysis includes eight studies, the study by Tyson et
al. is clearly the largest and greatly inﬂuences the results.
Enteral application of high-dose vitamin A was examined in
one study that did not show any long-term positive eﬀect
[54]. The current evidence solely supports the intramuscular
delivery of high-dose vitamin A to ELBW infants [53].
Neurodevelopmental outcomes at 18 to 22 months were
not diﬀerent in the two experimental groups; interestingly
there was also no diﬀerence in respiratory outcome at 18
to 22 months [55]. Evidence supports the use of high-dose
intramuscularvitaminAsupplementationfortheprevention
of BPD in premature infants <1000 grams although there are
no long-term beneﬁts in pulmonary or neurodevelopmental
outcome.
8.Inositol
Inositol is a phospholipid that enhances the synthesis and
secretion of surfactant phospholipids thereby improving
pulmonary function. A randomized controlled trial by Hall-
man et al. demonstrated lower oxygen and airway pressure
requirements with the use of intravenous inositol; however
very few patients received surfactant in this trial [56]. Within
the group receiving surfactant, there was no reduction in
BPD after inositol administration in this study. A Cochrane
meta-analysis that included all infants who received inositol
treatment showed a signiﬁcant reduction in death or BPD
compared to untreated controls [57]. No further studies to
conﬁrm these ﬁndings have been reported; it is possible that
the positive results previously found would no longer be
present in the surfactant era or that inositol administration
may beneﬁt a subpopulation of infants. Inositol is not cur-
rentlyrecommended forprevention of BPDbutfurther trials
may be warranted in the surfactant era to conﬁrm these
preliminary ﬁndings and to study the long-term eﬀects.
9.Antioxidants
(a) Superoxide Dismutase (SOD). F r e er a d i c a l sh a v eb e e n
implicated in the pathogenesis of BPD. Premature infants are
susceptibletooxidantinjurysincetheyarerelativelydeﬁcient
in antioxidant enzymes while being exposed to toxic oxygen
levels [58]. Preliminary animal and human studies have
provided evidence for a protective action of antioxidants
such as SOD in hyperoxia-induced acute and chronic lung
injury [59–61]. A randomized controlled trial studied if
recombinant CuZnSOD would decrease the incidence of
BPD in ventilated and surfactant-treated preterm infants
[62]. This trial enrolled 302 patients and showed that CuZn-
SOD can be given safely and is well tolerated intratracheally
butfoundnodiﬀerenceintheprimaryoutcomeofBPDat28
daysoflifeor36weekspostmenstrualage.Thestrikingresult
was a signiﬁcant decrease in several indicators of lung disease
in the treatment group over the ﬁrst year of life including
reduction in need for asthma medications, fewer emergency
department visits, and fewer hospitalizations suggesting a
delayed beneﬁcial response at one year of age in infants
<27 weeks gestation. The mechanism underlying this SOD-
mediated delayed beneﬁt is unclear but presumably involves
the disruption of the pathogenic reactive oxygen species. It
appears that the role of SOD in the management of BPD
may warrant further study. The long-term eﬀect of SOD in
other neonatal morbidities and the eﬀects of dosage, mode
of delivery, frequency, and type of preparation of SOD need
to be addressed in future trials.
(b) N Acetyl-Cysteine (NAC). Glutathione is an endogenous
scavenger of free radicals, which is relatively deﬁcient in6 International Journal of Pediatrics
prematureinfantswithdecreasinggestationalage[63].Ahola
et al. proposed use of NAC, a precursor of glutathione,
to ameliorate cellular injury from free radicals [64]. Intra-
venous NAC was administered for the ﬁrst six postnatal days
in a multicenter double blind placebo-controlled trial. In a
group of 391 infants weighing under 1000g, no signiﬁcant
diﬀerences were found in incidence or severity of BPD
between the NAC and placebo groups [64]. A follow-up
study showed no signiﬁcant diﬀerence in the lung function
between the two groups [65]. Long-term follow-up of these
infants will be required to determine potential delayed ben-
eﬁts.
(c) Tocopherol (Vitamin E) and Ascorbic Acid (Vitamin C).
Both Vitamin E and C could serve as scavengers of reactive
oxygen species produced during high oxygen exposure and
prevent lipid peroxidation. Randomized controlled trials
have shown no evidence that vitamin E supplementation
alone or in combination with vitamin C oﬀers protection
against BPD [66, 67].Although the mechanism is well estab-
lished, limited success has been achieved using antioxidants
and therefore their routine use is not recommended at
present. Potential limiting factors include radical formation
restricted to subcellular compartments, timing, dose, and
delivery of the drug, or perhaps a need for multiple agents
blocking diﬀerent pathways of reactive oxygen species. Alter-
natively, as the SOD trial has shown, lack of acute beneﬁt
does not preclude delayed beneﬁcial eﬀects on pulmonary
outcome. This underscores the importance of including
long-term outcomes in the design of randomized trials of
pharmacologic interventions for BPD.
10. InhaledNitric Oxide(iNO)
iNO is a selective pulmonary vasodilator that decreases pul-
monary vascular resistance without aﬀecting systemic vas-
cular tone [68]. The rationale for the use of iNO in the
prevention of BPD stems from animal and human studies
supporting an anti-inﬂammatory role for NO and beneﬁcial
eﬀects in lung structure and gas exchange [69–73]. Several
large clinical trials with diﬀerent study designs yielded
variable results [74–79]. These studies included iNO given
as prophylaxis to prevent BPD, as rescue therapy for severe
acute respiratory failure, and as treatment for severe BPD
in a variable patient population. One of the larger trials by
Ballard et al. enrolled intubated infants during the second
postnatal week and used a higher starting dose of iNO and
demonstrated a modest reduction in BPD in the treatment
group, but no diﬀerence in death [74]. While a modest
reduction in composite outcome of death or BPD was found
in a systematic review, there was no evidence of reduction
in rates of death alone or BPD in infants treated with iNO
compared to controls [68]. An individualized patient data
meta-analysis of randomized trials also found that routine
use of iNO for treatment of respiratory failure cannot be
recommended [80]. The variable results and diﬃculty in
interpretation of the numerous trials prompted an NIH
consensus development conference which concluded that
current evidence does not support use of iNO in early
routine, early rescue, or later rescue regimens in the care
of premature infants <34 weeks [81]. Future trials to deﬁne
the optimal dose, timing, and duration of iNO therapy in
prevention on BPD are warranted and are ongoing at the
time of this review.
11. Other Potential Therapies
11.1. Mesenchymal Stem Cell Therapy. The therapeutic
potential of stem cells is currently explored for a variety of
disorders. Intrinsic qualities of mesenchymal stem cells such
as their capacity to respond, migrate, and replace damaged
tissue make them an attractive candidate for prevention
and repair of neonatal lung injury. In animal models, bone
marrow-derivedmesenchymalstemcells(BMSCs)havebeen
shown to ameliorate injury in multiple organs including
heart, brain, kidney, and lung [82–85]. In neonatal rodent
modelsofBPD,allogenicBMSCshavebeenshowntoprevent
lung injury and lung inﬂammation [84–86]. This protection
was observed despite a very low level of BMSC engraftment
in the lungs. In fact, even more profound improvement in
alveolar simpliﬁcation and vascular injury was seen after
delivery of BMSC-conditioned media indicating that a
paracrine mechanism is likely involved [84]. Further studies
in animal models of BPD are needed to address whether
BMSCs can provide protection by a paracrine immunomod-
ulatory response leading to release of speciﬁc growth factors
and anti-inﬂammatory molecules [86].
12. Conclusion
Well-conducted clinical trials and meta-analyses have
demonstrated a lack of signiﬁcant impact of several phar-
macologic therapies [87]. Despite this, many pharmacologic
therapies are currently practiced because of transient bene-
ﬁcial eﬀects and lack of alternatives. As our understanding
of the complex and multifactorial pathophysiology of BPD
improves,itbecomesclearthattargetingindividualpathways
is unlikely to have a signiﬁcant impact on outcome. A mul-
tidrug approach addressing several pathways simultaneously
may have a more signiﬁcant impact on the incidence and
progression of the disease. We need to continue to work to
understand the basic mechanisms of neonatal lung devel-
opment, injury, and repair. In addition, targeted therapeutic
a p p r o a c h e sb a s e do nh o s tf a c t o r sa n ds p e c i ﬁ cp a t i e n tg e n e t i c
and epigenetic makeup may allow better therapeutic choices.
Some prediction tools have been developed based on risk
factors to help provide prognostic information and facilitate
identiﬁcation of infants who may beneﬁt from therapies
available [88]. Continued clinical practice optimization with
minimization of ventilator-induced lung injury, oxygen
toxicity, and infection as well as continued optimization of
nutrition should also continue to be pursued. As we gain
new insight into the disease process and evaluate novel
approaches, it is essential to focus not only on short-
term outcomes and safety proﬁles but also on long-term
pulmonary and neurodevelopmental outcomes.International Journal of Pediatrics 7
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